Molecular Formula | C26H54NO7P |
Molar Mass | 523.68 |
Melting Point | 247 °C |
Appearance | lyophilized powder |
BRN | 3574588 |
Storage Condition | -20°C |
In vitro study | C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR −/− but not PAFR +/+ cultures. C16-PAF (1 μM) elicits neuronal death in PAFR −/− cells infected with EGFP alone. C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR −/− neurons. C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor. C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner. Cell Viability Assay Cell Line: Cerebellar granule neurons (CGNs) from PAFR −/− and PAFR +/+ mice Concentration: 0.5-1.5 μM Incubation Time: 24 hours Result: Elicited significant concentration-dependent neuronal loss in PAFR −/− but not PAFR +/+ cultures in serum-free media. Western Blot Analysis Cell Line: CGNs Concentration: 1 μM Incubation Time: 24 hours Result: Activated caspase 7 but not caspase 3 in PAFR −/− neurons. |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R38 - Irritating to the skin R40 - Limited evidence of a carcinogenic effect R48/20/22 - |
Safety Description | S36/37 - Wear suitable protective clothing and gloves. S24/25 - Avoid contact with skin and eyes. S22 - Do not breathe dust. |
UN IDs | UN 1888 6.1/PG 3 |
WGK Germany | 3 |
RTECS | EC6060000 |
FLUKA BRAND F CODES | 10-21 |
Biological activity | C16-PAF (PAF (C16)) is a phospholipid medium, a platelet activating factor, and a ligand for PAF G protein coupled receptor (PAFR). C16-PAF showed anti-apoptotic effects and inhibited caspase-dependent death by activating PAFR. C16-PAF are effective MAPK and MEK/ERK activators. C16-PAF induces increased vascular permeability. |
target | Human Endogenous Metabolite ERK MEK |
in vitro study | C16-PAF (PAF (C16); 0.5-1.5 μM; For 24 hours) elicits significant concentration-dependent neuronal loss in PAFR −/but not PAFR / cultures. C16-PAF (1 μM) elicits neuronal death in PAFR −/cells infected with EGFP alone. C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR/neurons. C16-PAF is synthesized by two distinct pathways; The remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor. C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG Growth in a Time-dependent Manner. Cell Viability Assay Cell Line: Cerebellar granule neurons (CGNs) from PAFR/and PAFR/MICE Concentration: 0.5-1.5 μM Incubation Time: 24 Hours Result: elicited significant concentration-dependent neuronal loss in PAFR/but not PAFR / cultures in series-free media. Western Blot Analysis Cell Line: CGNs Concentration: 1 μM Incubation Time: 24 hours Result: Activated caspase 7 but not caspase 3 in PAFR/neurons. |
Cell Line: | Cerebellar granule neurons (CGNs) from PAFR −/− and PAFR +/+ mice CGNs |
Concentration: | 0.5-1.5 μM 1 μM |
Incubation Time: | 24 hours 24 hours |
Result: | Elicited significant concentration-dependent neuronal loss in PAFR −/− but not PAFR +/+ cultures in serum-free media. Activated caspase 7 but not caspase 3 in PAFR −/− neurons. |